Xuguang Zhu1, Sheue-yann Cheng. 1. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4264, USA.
Abstract
PURPOSE OF REVIEW: Thyroid hormone (3,3',5-triiodo-L-thyronine) plays an important role in thermogenesis and maintenance of lipid homeostasis. The present article reviews the evidence that 3,3',5-triiodo-L-thyronine regulates lipid metabolism via thyroid hormone receptors, focusing particularly on in-vivo findings using genetically engineered mice. RECENT FINDINGS: That lipid metabolism is regulated via thyroid hormone receptor isoforms in a tissue-dependent manner was recently uncovered by using knockin mutant mice harboring an identical mutation in the Thra gene (Thra1(PV) mouse) or the Thrb gene (Thrb(PV) mouse). The mutation in the Thra gene dramatically decreases the mass of both white adipose tissue and liver. In contrast, the mutation in the Thrb gene markedly increases the mass of liver with an excess depot of lipids, but no significant abnormality is observed in white adipose tissue. Molecular studies show that the expression of lipogenic genes is decreased in white adipose tissue of Thra1(PV) mice, but not in Thrb(PV) mice. Markedly increased lipogenic enzyme expression, and decreased fatty acid beta-oxidation activity contribute to the adipogenic steatosis and lipid accumulation in the liver of Thrb(PV) mice. In contrast, reduced expression of genes critical for lipogenesis mediates decreased liver mass with lipid scarcity in Thra1(PV) mice. SUMMARY: Studies using Thra1(PV) and Thrb(PV) mice indicate that apo-thyroid hormone receptor-beta and apo-thyroid hormone receptor-alpha-1 mediate distinct deleterious effects on lipid metabolism. Thus, both thyroid hormone receptor isoforms contribute to the pathogenesis of lipid abnormalities in hypothyroidism, but in a target tissue-dependent manner. These studies suggest that thyroid hormone receptor isoform-specific ligands could be designed as therapeutic targets for lipid abnormalities.
PURPOSE OF REVIEW: Thyroid hormone (3,3',5-triiodo-L-thyronine) plays an important role in thermogenesis and maintenance of lipid homeostasis. The present article reviews the evidence that 3,3',5-triiodo-L-thyronine regulates lipid metabolism via thyroid hormone receptors, focusing particularly on in-vivo findings using genetically engineered mice. RECENT FINDINGS: That lipid metabolism is regulated via thyroid hormone receptor isoforms in a tissue-dependent manner was recently uncovered by using knockin mutant mice harboring an identical mutation in the Thra gene (Thra1(PV) mouse) or the Thrb gene (Thrb(PV) mouse). The mutation in the Thra gene dramatically decreases the mass of both white adipose tissue and liver. In contrast, the mutation in the Thrb gene markedly increases the mass of liver with an excess depot of lipids, but no significant abnormality is observed in white adipose tissue. Molecular studies show that the expression of lipogenic genes is decreased in white adipose tissue of Thra1(PV) mice, but not in Thrb(PV) mice. Markedly increased lipogenic enzyme expression, and decreased fatty acid beta-oxidation activity contribute to the adipogenic steatosis and lipid accumulation in the liver of Thrb(PV) mice. In contrast, reduced expression of genes critical for lipogenesis mediates decreased liver mass with lipid scarcity in Thra1(PV) mice. SUMMARY: Studies using Thra1(PV) and Thrb(PV) mice indicate that apo-thyroid hormone receptor-beta and apo-thyroid hormone receptor-alpha-1 mediate distinct deleterious effects on lipid metabolism. Thus, both thyroid hormone receptor isoforms contribute to the pathogenesis of lipid abnormalities in hypothyroidism, but in a target tissue-dependent manner. These studies suggest that thyroid hormone receptor isoform-specific ligands could be designed as therapeutic targets for lipid abnormalities.
Authors: Catherine S Mitchell; David B Savage; Sylvie Dufour; Nadia Schoenmakers; Peter Murgatroyd; Douglas Befroy; David Halsall; Samantha Northcott; Philippa Raymond-Barker; Suzanne Curran; Elana Henning; Julia Keogh; Penny Owen; John Lazarus; Douglas L Rothman; I Sadaf Farooqi; Gerald I Shulman; Krishna Chatterjee; Kitt Falk Petersen Journal: J Clin Invest Date: 2010-03-08 Impact factor: 14.808
Authors: Paul W Ladenson; Jens D Kristensen; E Chester Ridgway; Anders G Olsson; Bo Carlsson; Irwin Klein; John D Baxter; Bo Angelin Journal: N Engl J Med Date: 2010-03-11 Impact factor: 91.245
Authors: Miriam O Ribeiro; Suzy D C Bianco; Masahiro Kaneshige; James J Schultz; Sheue-yann Cheng; Antonio C Bianco; Gregory A Brent Journal: Endocrinology Date: 2009-11-11 Impact factor: 4.736
Authors: Beatriz S Amorim; Cintia B Ueta; Beatriz C G Freitas; Renata J Nassif; Cecília Helena de Azevedo Gouveia; Marcelo A Christoffolete; Anselmo S Moriscot; Carmen Lucia Lancelloti; Flávia Llimona; Hermes Vieira Barbeiro; Heraldo Possolo de Souza; Sergio Catanozi; Marisa Passarelli; Marcelo S Aoki; Antonio C Bianco; Miriam O Ribeiro Journal: J Endocrinol Date: 2009-08-27 Impact factor: 4.286
Authors: Jussi Pihlajamäki; Tanner Boes; Eun-Young Kim; Farrell Dearie; Brian W Kim; Joshua Schroeder; Edward Mun; Imad Nasser; Peter J Park; Antonio C Bianco; Allison B Goldfine; Mary Elizabeth Patti Journal: J Clin Endocrinol Metab Date: 2009-06-23 Impact factor: 5.958